Merck & Co.’s shares rise over 7% thanks to new positive clinical results from Keytruda

Merck & Co.’s shares (Wall Street) have risen by over 7% as trading opened, following positive results from the Phase III clinical trial Keynote-189. The trial has been conducted on patients with non-squamous non-small cell lung cancer, treated with Keytruda in combination with chemotherapy. The results have demonstrated that the combo is significantly better than chemotherapy alone and extends patients’ life expectancy. By sharp contrast, competitor Bristol-Myers Squibb’s shares have lost 3%.
(Source: Merck & Co.)